Table 1. Baseline Characteristics of Patients by Treatment Assignment.
| Patient-Level Characteristicsa | Methotrexate (n = 107) | Mycophenolate Mofetil (n = 109) |
|---|---|---|
| Age, median (IQR), y | 36 (26-50) | 41 (31-51) |
| Female sex | 75 (70.1) | 60 (55.0) |
| Male sex | 32 (29.9) | 49 (45.0) |
| Hispanic ethnicity | 5 (4.7) | 7 (6.4) |
| Raceb | ||
| Indian subcontinent | 70 (65.4) | 69 (63.3) |
| White | 25 (23.4) | 22 (20.2) |
| Asian | 5 (4.7) | 6 (5.5) |
| Middle Eastern | 5 (4.7) | 5 (4.6) |
| Black | 3 (2.8) | 6 (5.5) |
| Native American | 2 (1.9) | 1 (0.9) |
| Pacific Islander | 1 (0.9) | 3 (2.8) |
| Uveitis diagnosis | ||
| Vogt-Koyanagi-Harada disease | 49 (45.8) | 44 (40.4) |
| Undifferentiated | 22 (20.6) | 20 (18.3) |
| Retinal vasculitis | 8 (7.5) | 13 (11.9) |
| Sarcoidosis | 7 (6.5) | 8 (7.3) |
| Sympathetic ophthalmia | 3 (2.8) | 8 (7.3) |
| Behçet disease | 5 (4.7) | 3 (2.8) |
| Pars planitis | 2 (1.9) | 5 (4.6) |
| Birdshot chorioretinopathy | 3 (2.8) | 3 (2.8) |
| Other | 8 (7.5) | 5 (4.6) |
| Bilateral uveitis | 99 (92.5) | 92 (84.4) |
| Duration of uveitis, median (IQR), d | 135 (20-550) | 122 (21-783) |
| Anatomic location, based on entire uveitis historyc | ||
| Panuveitis | 60 (56.1) | 61 (56.0) |
| Posterior uveitis | 24 (22.4) | 25 (22.9) |
| Anterior uveitis and intermediate uveitis | 15 (14.0) | 14 (12.8) |
| Intermediate uveitis | 8 (7.5) | 9 (8.3) |
| Systemic corticosteroid use | ||
| Maximum dose of oral prednisone or equivalent in past 180 days, median (IQR), mgd | 50 (40-60) | 50 (40-75) |
| Oral prednisone at baseline, median (IQR), mg | 50 (40-60) | 50 (40-60) |
| Prior treatment with immunosuppressive therapy | 8 (7.5) | 7 (6.4) |
| Eye-Level Characteristics |
Methotrexate (n = 206 eyes) |
Mycophenolate Mofetil (n = 201 eyes) |
| Inflammation at baseline | ||
| Anterior chamber cells | 205 (99.5) | 201 (100.0) |
| 0 | 84 (41.0) | 87 (43.3) |
| 0.5+ | 53 (25.9) | 47 (23.4) |
| 1+ | 46 (22.4) | 47 (23.4) |
| ≥2+ | 22 (10.7) | 20 (10.0) |
| Anterior vitreous cells | 202 (98.1) | 200 (99.5) |
| 0 | 34 (16.8) | 33 (16.5) |
| 0.5+ | 40 (19.8) | 48 (24.0) |
| 1+ | 52 (25.7) | 51 (25.5) |
| ≥2+ | 76 (37.6) | 68 (34.0) |
| Vitreous haze | 202 (98.1) | 200 (99.5) |
| 0 | 85 (42.1) | 97 (48.5) |
| 0.5+ | 30 (14.9) | 34 (17.0) |
| 1+ | 50 (24.8) | 30 (15.0) |
| ≥2+ | 37 (18.3) | 39 (19.5) |
| Active retinal or choroidal lesions, n/N (%) | 125/202 (61.9) | 119/200 (59.5) |
| Macular edemae | 42 (20.4) | 55 (27.3) |
| Central subfield thickness, median (IQR), μmf | 359.0 (331.5-449.5) | 342.0 (316.0-398.5) |
| LogMAR visual acuity, median (IQR)g | 0.28 (0.03-0.52) | 0.30 (0.08-0.60) |
Abbreviations: IQR, interquartile range; logMAR, logarithm of the minimum angle of resolution.
a
Values are reported as No. (%) unless otherwise indicated.
b
Seven patients listed being of more than 1 racial heritage.
c
Anatomic location was assessed given all medical records available.
d
Corticosteroids in the past 180 days included oral, subcutaneous, and intravenous, and were adjusted to equivalent calculations of oral prednisone.
e
Macular edema excluded patients with Vogt-Koyanagi-Harada disease who had a serious retinal detachment.
f
Characteristic was reported in patients with macular edema.
g
Indicates best-corrected visual acuity of uveitic eyes only.